Try our Advanced Search for more refined results

BIER v. ENDO INTERNATIONAL, PLC et al

  1. December 13, 2019

    Endo's $82.5M Deal In Suit Over Opioid Drug Gets Final OK

    An $82.5 million cash deal ending investors' claims that pharmaceutical company Endo International PLC hid safety issues with an opioid drug was finalized in Pennsylvania federal court Friday.

  2. June 14, 2019

    Endo Fights Investor's Cert. Bid In Opioid Stock-Drop Suit

    Endo International PLC asked a Pennsylvania federal court Thursday to reject an institutional investor's class certification bid in a suit accusing the pharmaceutical company of hiding safety issues with an opioid drug, arguing the investor has little in common with the other stockholders.

  3. May 23, 2019

    Endo Investors Seek Class Cert. In Opioid Stock-Drop Suit

    Endo International PLC investors have asked a Pennsylvania federal court to grant them class certification in their suit claiming the pharmaceutical company knowingly misrepresented the safety of its opioid drug Opana, leading to a significant stock drop when it was forcibly removed from the market.

  4. December 11, 2018

    Endo Must Face Stock-Drop Claims In Opioid Safety Suit

    Endo International PLC and several of its executives must face an investor suit alleging the company knowingly misrepresented the safety of its Opana opioid, leading to a significant stock drop when the drug was forcibly removed from the market, after a Pennsylvania federal judge said Monday that the shareholders sufficiently pled their claims.

  5. May 07, 2018

    Endo Shareholders Fight Bid To Toss Opioid Safety Suit

    A proposed class of Endo International PLC shareholders on Friday blasted Endo's argument that their suit should be tossed because the drugmaker couldn't have foreseen the fallout of the opioid crisis, telling a Pennsylvania federal judge the company knowingly misrepresented the safety of its Opana drug before pulling it from the market.

  6. August 21, 2017

    Endo Misrepresented Opioid Drug Safety, Shareholder Says

    Endo International PLC misrepresented the safety of its opioid Opana ER, ultimately causing the company to pull the drug from the market and the stock price to plunge, according to a proposed class action filed in Pennsylvania federal court.